JUMP — How common sarcopenia and 'chemobrain' are after cancer
Prevalence of Sarcopenia and Chemobrain in Post-cancer Patients
This project will see how common muscle loss (sarcopenia) and thinking problems ('chemobrain') are in adults who have finished cancer treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 74 Years |
| Sex | All |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Locations | 1 site (Pierre-Bénite) |
| Trial ID | NCT05800535 on ClinicalTrials.gov |
What this trial studies
JUMP is an observational project that brings post-cancer patients to a one-day assessment including standard labs and focused checks for muscle deconditioning and cognitive changes. Participants undergo blood tests (glycaemia, creatinine, liver tests, blood count) and evaluations for sarcopenia and cognitive function. After the assessment day, patients are referred to appropriate local services such as adapted physical activity, sports-for-health programs, or rehabilitation at Henry Gabriel Hospital. The project enrolls adults aged 18–74 with a range of prior cancer types who completed oncology treatment and attended the post-cancer assessment day at Hospices Civils de Lyon.
Who should consider this trial
Good fit: Adults aged 18 to 74 who have completed treatment for cancers such as breast, lung, melanoma, testicular, bladder, kidney, ovarian, colon, pancreatic, or hematologic malignancies and who attend the post-cancer assessment day are eligible.
Not a fit: People under 18 or over 74, those who did not receive chemotherapy, and patients who decline participation are not eligible and would not benefit from this program.
Why it matters
Potential benefit: If successful, this work could help identify patients who need physical rehabilitation or cognitive support and speed referrals to services that improve post-cancer quality of life.
How similar studies have performed: Previous observational work has repeatedly found that both sarcopenia and cancer-related cognitive changes are common after treatment, so this project builds on established findings rather than testing an entirely novel concept.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age : 18 to 74 years * localization of the primitive: breast, lung, melanoma, testicle, bladder, kidney, ovary, colon and pancreas, hemopathy * patient who benefited from the post-cancer assessment day- Exclusion Criteria: * Under 18years * Over 74 years * Patient who did not received any chemical treatment * Patient who do not wish to participate
Where this trial is running
Pierre-Bénite
- Service de Rhumatologie, Hospices Civils de Lyon, Groupement Hospitalier Lyon Sud — Pierre-Bénite, France (Recruiting)
Study contacts
- Study coordinator: Cyrille CONFAVREUX, MD
- Email: Cyrille.confavreux@chu-lyon.fr
- Phone: +334 78 86 12 31
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.